# Doron Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/doron-therapeutics

- Industry: Biotechnology
- Headquarters: Chapel Hill, US
- Website: www.dorontherapeutics.com
- Total disclosed funding: $11M
- Latest round: Series A (Nov 25, 2024)
- Investors on record: 1

## About

Founded in 2023 and based in North Carolina, US, Doron Therapeutics, Inc. operates as a biotechnology research company that develops therapeutics for osteoarthritis treatment. In November 2024, Doron Therapeutics raised USD 11 million in series A funding led by investor Sprim Ventures. The firm as of November 2024, is led by its CEO, Alessandra Pavesio.

Doron Therapeutics focuses on developing MOTYS™, an intra-articular biologic drug derived from placental tissue to treat osteoarthritis symptoms. MOTYS™ contains growth factors with anti-inflammatory, tissue-protective, and regenerative properties, aimed at reducing pain and improving mobility for patients with osteoarthritis. The product is primarily marketed in North America and Europe, targeting healthcare providers, clinics, and hospitals that serve osteoarthritis patients.

The company plans to utilize the November 2024 funding to advance its MOTYS osteoarthritis drug into phase 3 clinical studies.

## Funding rounds

- Series A, Nov 25, 2024, $11M — Sprim Ventures

## Investors

- Sprim Ventures (https://capitalatlas.ai/funds/sprim-ventures) — Series A